Top 10 Wall Street Losers of 2016
These Companies Lost the Most in a Down Year for Biopharma Stocks
Reading miRNAs for Clinical Meaning
Single miRNAs Don’t Say Much, but They May Become Eloquent Biomarkers if We Take Their Testimony in Context
Sorting Out the CRISPR Patent Case
Sounds of Science Podcast
Good Assays for Bad Immunogenicity
Avoid “Bad” Immunogenicity by Using Assays That Are More Sensitive and Can Adapt to Increasingly Complex and Specialized Drugs
For full access to this article login to GEN Select now.
Systems Biology Alters Drug Development
Omics Tools Revitalize Field, but Deciphering High-throughput Data Is Still a Major Obstacle
- Research and development costs by pharmaceutical companies rose to an estimated $55.2 billion in 2006, with costs to develop a biologic drug reaching $1.2 billion. The potential of the Human Genome Project has yet to be fully realized, but many companies are starting to embrace systems biology as a ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.